Abstract CT215: RELAY, ramucirumab plus erlotinib (RAM+ERL) versus placebo plus erlotinib (PBO+ERL) in previously untreated <i>EGFR</i> mutation-positive metastatic NSCLC: Next generation sequencing (NGS) results

Authors: Edward Garon, Martin Reck, Kazuto Nishio, John Victor Heymach, Makoto Nishio, Silvia Novello, Luis Paz-Ares, Sanjay Popat, Santiago Ponce Aix, Sameera Wijayawardana, Rebecca R. Hozak, Carla Visseren-Grul, Kazuhiko Nakagawa

Published: 2020-09-04

DOI: 10.1158/1538-7445.am2020-ct215

Source: Full article